The Base Excision Repair Pathway

Base excision repair (BER) represents a fundamental and highly conserved cellular defense system, indispensable for maintaining the integrity of the genome in all living organisms. This pathway serves as the primary mechanism for the correction of a vast array of small, non-helix-distorting DNA base lesions that arise continuously from endogenous metabolic processes, such as oxidative stress and spontaneous hydrolysis, as well as from exposure to exogenous genotoxic agents. The BER process is a meticulously orchestrated enzymatic cascade involving the sequential action of DNA glycosylases for lesion recognition and excision, AP endonucleases for backbone incision, DNA polymerases for gap filling and end processing, and DNA ligases for sealing the final nick. This review provides a comprehensive and critical analysis of the BER pathway, dissecting its intricate biochemical mechanisms...

The chemical stability of the deoxyribonucleic acid (DNA) molecule is paramount for the faithful storage and transmission of genetic information. However, this stability is under constant assault from a multitude of endogenous and exogenous sources, resulting in a relentless barrage of DNA damage. Endogenous damage, arising from the cell's own metabolic activities, is particularly pervasive. Reactive oxygen species (ROS), which are inevitable byproducts of normal aerobic metabolism in the mitochondria, are a major source of oxidative damage to DNA bases.

If left unrepaired, these DNA lesions can have profound and deleterious consequences. Many modified bases are promutagenic, as they can be misread by DNA polymerases during replication, leading to the incorporation of incorrect nucleotides and the fixation of permanent mutations in the genome. Other lesions can be cytotoxic, physically blocking the progression of DNA or RNA polymerases, which can arrest replication and transcription, trigger chromosomal rearrangements, or induce cellular senescence or apoptosis. The cumulative effect of this unrepaired damage is a primary driver of genomic instability, a hallmark of cancer, and is strongly implicated in the pathophysiology of the aging process and a spectrum of neurodegenerative disorders.

The BER pathway is a model of enzymatic efficiency and coordination, proceeding through a series of discrete steps catalyzed by a dedicated set of proteins. This section provides a detailed mechanistic examination of this cascade, from the initial recognition of damage to the final restoration of the DNA backbone.

The initiation of BER is the sole responsibility of the DNA glycosylase superfamily, a diverse group of enzymes tasked with the critical first step of identifying and excising damaged or inappropriate bases from the vast expanse of the genome.

The BER pathway is not a static, monolithic entity. Its activity is dynamically regulated and tailored to the specific type of lesion, the physiological state of the cell, and the subcellular location of the damage. This higher-level orchestration ensures that repair is deployed efficiently and safely, interfacing seamlessly with other core cellular processes like cell cycle progression, DNA replication, and transcription.

After the initial steps of base excision and backbone incision, the BER pathway diverges into two major sub-pathways that differ in the length of the synthesized repair patch and the enzymatic machinery employed.

The intricate biochemical machinery of BER is encoded by a specific set of genes within the human genome. Understanding the organization, regulation, and variation of these genes is fundamental to linking the molecular mechanisms of repair to heritable disease predispositions and individual differences in susceptibility to DNA damage.

The human BER pathway is a complex network involving at least 30 proteins. The core components, responsible for the primary steps of repair, are encoded by a well-defined set of genes. This includes the 11 known DNA glycosylase genes (UNG, SMUG1, TDG, MBD4, MPG, MUTYH, OGG1, NTHL1, NEIL1, NEIL2, NEIL3), the genes for the two major AP endonucleases (APEX1, APEX2), the genes for the key DNA polymerases involved (POLB, POLL, POLD1, POLE), the genes for the DNA ligases (LIG3, LIG1), and genes for essential scaffolding and accessory factors (XRCC1, PCNA, FEN1, PARP1).

DNA is not a static molecule; it is the dynamic template for the fundamental processes of replication and transcription. The BER pathway must therefore operate in the context of these complex molecular machineries, leading to intricate and sometimes hazardous interactions. The coordination of repair with these processes is essential to prevent the conversion of simple base lesions into more severe forms of damage, such as stalled forks and double-strand breaks.

The interface between BER and DNA replication is a critical juncture for maintaining genome stability. The progression of a replication fork through a region of DNA containing an unrepaired base lesion or a BER intermediate poses a significant threat.

The base excision repair pathway plays a profoundly dichotomous role in human health and disease. Its faithful execution is essential for preventing the mutations that can initiate cancer and for preserving the long-term integrity of the neuronal genome. Yet, its activity can also be co-opted by cancer cells to promote survival and drug resistance, and its gradual decline is a key feature of the aging process. This section explores this complex and often paradoxical relationship.

The connection between BER and cancer is a quintessential example of a double-edged sword. Both deficiency and overexpression of the pathway are intimately linked to carcinogenesis and tumor progression.

The central role of base excision repair in both preventing mutagenesis and enabling cancer cell survival has made it a focal point for the development of novel therapeutic strategies, particularly in oncology. By manipulating the BER pathway, researchers aim to either enhance the efficacy of conventional treatments or exploit cancer-specific vulnerabilities to selectively eliminate tumor cells.

Two primary strategies underpin the therapeutic targeting of BER: sensitization and synthetic lethality.